Neostem Inc. (Nasdaq: NBS) reported disappointing results from a trial of its cardiac stem cell therapy NBS10. Shares of the biotechnology firm plummeted $2.19 to $4.59.
Disappointing trial results for Neostem
November 18, 2014 at 12:38 PM EST